Intech Investment Management LLC Raises Stock Position in Collegium Pharmaceutical, Inc. $COLL

Intech Investment Management LLC lifted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 73,908 shares of the specialty pharmaceutical company’s stock after buying an additional 6,776 shares during the period. Intech Investment Management LLC owned approximately 0.23% of Collegium Pharmaceutical worth $2,206,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after purchasing an additional 339 shares in the last quarter. SummerHaven Investment Management LLC lifted its stake in Collegium Pharmaceutical by 1.9% during the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $727,000 after acquiring an additional 448 shares during the period. Farther Finance Advisors LLC lifted its stake in Collegium Pharmaceutical by 4.5% during the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company’s stock valued at $326,000 after acquiring an additional 477 shares during the period. Virtus Fund Advisers LLC lifted its stake in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 565 shares during the period. Finally, SG Americas Securities LLC lifted its stake in Collegium Pharmaceutical by 4.2% during the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company’s stock valued at $426,000 after acquiring an additional 578 shares during the period.

Analyst Upgrades and Downgrades

COLL has been the subject of several analyst reports. HC Wainwright upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 target price for the company in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $42.33.

Insider Activity

In related news, Director John Gordon Freund sold 11,659 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $34.36, for a total value of $400,603.24. Following the sale, the director owned 23,129 shares of the company’s stock, valued at $794,712.44. This trade represents a 33.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gino Santini sold 5,405 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $37.19, for a total transaction of $201,011.95. Following the completion of the transaction, the director owned 95,042 shares in the company, valued at $3,534,611.98. This represents a 5.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,792 shares of company stock worth $2,084,207 in the last ninety days. 2.51% of the stock is owned by insiders.

Collegium Pharmaceutical Stock Down 6.4%

Shares of COLL opened at $34.92 on Tuesday. The stock has a market capitalization of $1.10 billion, a PE ratio of 33.58 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. The company’s 50-day simple moving average is $35.08 and its 200-day simple moving average is $31.00.

Collegium Pharmaceutical declared that its Board of Directors has approved a stock buyback plan on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.